ASCO 2025 | ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more

ASCO 2025 is big for all three major subtypes of breast cancer. Let’s start with the first one, the hormone positive HER2 negative. We’re gonna get a big study that can define the field going forward for the endocrine sensitive hormone receptor cause HER2 negative breast cancer. That’s the SERENA-6 study. Forever we treat our breast cancer patient until clinical or radiological progression. It’s the first time we’re gonna have a study where we’re gonna act early when you have molecular progression based on the immersion of a resistant mutation called ESR1. We’re very excited about it. It’s going to define a new paradigm shift in how we treat those patients. So that’s the most common subtype of breast cancer. The second subtype is HER2 positive breast cancer. We’re going to have also a pivotal study, the DESTINY-Breast09, where we’re going to look at the use of ADCs instead of chemotherapy combined with HER2-directed therapy, which has been the standard of care for over a decade now by the Cleopatra regimen. So that’s the DESTINY-Breast09 hopefully is gonna set up a new standard of care using antibody drug conjugate. The next frontier in the world of oncology and similarly for the third subtype of breast cancer the triple negatives we can have the ASCENT-04 study another antibody drug conjugate targeting Trope2 that can be combined with immunotherapy Pembrolizumab also is gonna define this field going forward and can be part of the first-line therapy for triple negative that are immunogenic with a positive PD-L1. So all three subtypes at this meeting will have pivotal studies that can redefine the field.